Cargando…
Microangiopathy in multiple myeloma: a case of carfilzomib-induced secondary thrombotic microangiopathy successfully treated with plasma exchange and complement inhibition
BACKGROUND: Thrombotic microangiopathy (TMA) is a potentially organ and life-threatening condition affecting patients with multiple myeloma (MM). Cases of proteasome inhibitor-induced TMA and specifically carfilzomib-induced TMA have been rarely reported and standards for diagnostic workup and treat...
Autores principales: | Catanese, Lorenzo, Link, Katharina, Rupprecht, Harald |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278274/ https://www.ncbi.nlm.nih.gov/pubmed/37337151 http://dx.doi.org/10.1186/s12882-023-03228-9 |
Ejemplares similares
-
Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathy
por: Moscvin, Maria, et al.
Publicado: (2023) -
Two cases of carfilzomib‐induced thrombotic microangiopathy successfully treated with Eculizumab in multiple myeloma
por: Rassner, Michael, et al.
Publicado: (2021) -
Complement in Secondary Thrombotic Microangiopathy
por: Palma, Lilian Monteiro Pereira, et al.
Publicado: (2020) -
Carfilzomib-Induced Thrombotic Microangiopathy: Focus on Pathogenesis
por: Eigbire-Molen, Odianosen, et al.
Publicado: (2022) -
Genetic and Functional Evidence of Complement Dysregulation in Multiple Myeloma Patients with Carfilzomib-Induced Thrombotic Microangiopathy Compared to Controls
por: Gavriilaki, Eleni, et al.
Publicado: (2022)